EirGenix Inc. (6589)

Overview

EirGenix Inc. is a comprehensive contract development and manufacturing organization (CDMO) that serves the global biopharmaceutical industry. Established in 2012 and based in New Taipei City, Taiwan, the company operates on an international scale. EirGenix provides a wide array of services that encompass cell line development, process development, analytical and quality control, as well as cGMP manufacturing for both mammalian and microbial systems. It specializes in the creation of antibody-drug conjugates and offers extensive expertise in biosimilar development and manufacturing. Alongside its service offerings, EirGenix is actively engaged in the development of several biosimilars and original biologics focused mainly on cancer treatment, reflecting its commitment to advancing healthcare and treatment options.

Products and Services

• Cell Line Development, Process Development, Analytical and Quality Control, cGMP Manufacturing (Mammalian and Microbial system), and Antibody-Drug Conjugate Services

  EirGenix provides a comprehensive suite of CDMO services targeted at the biopharmaceutical industry, supporting the development and manufacturing processes for both mammalian and microbial systems. This encompasses everything from the initial cell line development phases through to the final stages of cGMP manufacturing, along with thorough analytical and quality control measures. The company also specializes in the creation of antibody-drug conjugates, offering tailored services for the development of these complex therapies.

• EG12014/EGI014 (Trastuzumab Biosimilar)

  This product is a biosimilar of Trastuzumab, designed for the treatment of cancer and is currently awaiting biologics license approval. A biosimilar to Trastuzumab represents a significant development in making cancer treatments more accessible and affordable.

• EG1206A (Pertuzumab Biosimilar)

  A biosimilar of Pertuzumab, EG1206A is under development for cancer treatment, currently in the Phase I clinical trial stage. Pertuzumab is used in treating breast cancer, and this biosimilar aims to provide a more cost-effective treatment option.

• EG13074

  This product is in the preclinical stage of development, indicated for cancer treatment. While specific details are sparse, its positioning in the preclinical stage underscores EirGenix's commitment to expanding its pipeline of cancer therapeutics.

• TSY0110 (EG12043) (Antibody-Drug Conjugate)

  Currently under preclinical development, TSY0110/EG12043 is an antibody-drug conjugate aimed at treating cancer. This reflects the company's expertise in antibody-drug conjugate technology and its potential application in oncology.

• EG12021 (Bevacizumab Biosimilar)

  EG12021 is a biosimilar of Bevacizumab, currently in the preclinical stage and aimed at treating cancer. Bevacizumab is a monoclonal antibody used in various cancer treatments, and by developing a biosimilar, EirGenix aims to enhance accessibility to effective cancer therapies.

• EG62054 (Biosimilar)

  This product is another biosimilar currently in the preclinical development stage. Although details on the reference product are not provided, EG62054 represents part of EirGenix's broader strategy to develop biosimilar products that can improve patient access to critical medications.

• COVID-19 Antigen Rapid Test

  In response to the global COVID-19 pandemic, EirGenix manufactures and sells a COVID-19 antigen rapid test, providing a critical tool for the diagnosis and management of COVID-19 infections.

• EG74032 (CRM197 Carrier Protein)

  EG74032 is a CRM197 carrier protein, part of the company's portfolio of biologic raw materials. CRM197 is used as a carrier protein in conjugate vaccines, indicating EirGenix's involvement in vaccine development and production.